BREAKTHROUGH RESEARCH: Just announced from MYOS RENS Technology

UPDATE:  August 15th, 2019.  This article was written years ago and now my opinion has changed on it.  I think product is WEAK at best.

Here is great news and a myostatin inhibitor product I totally stand behind and recommend.  I’m thrilled with this press release.  So excited that I had to put up this blog post right now.  I put YEARS into this, yes, blood, sweat, and tears.

I was about to leave my office, head home and crack open a nice cold one and eat some chicken wings but then this came into my inbox.  Now some of you may or may not know, but I had a part in this product.  And I can tell you this.  It is 100% legitimate.  I know for a fact that this myostatin inhibitor supplement DOES contain ACTIVE follistatin.  I have personally taken this product.  What you will get out of it is an ANTI-CATABOLIC effect.  I feel that it elicits a strong anti-muscle wasting effect.  If you’re cutting weight, this is ideal for you.

Here’s the quick story behind the myostatin inhibitor product.  I helped create it.  MYOS REN then bought me out.  I do own shares of MYOS REN.  After they had bought me out, they licensed it to MHP.  MHP sold it as this product.

[clickToTweet tweet=”Breaking Muscle news: No other supplement has research like this showing a reduction in myostatin” quote=”MYOS REN just released this which is cool. No other supplement has research like this indicating a decline in myostatin. “] Without a doubt, this product will reduce myostatin in your body.  And listen, if you have any questions about this product like how it was created, how it works, or how to use it call me up.  800-343-1803 or message me on Facebook.   I can tell you an excellent story about this product.

Myostatin Inhibitor

MYOS RENS Technology Inc. has just released the following news:

MYOS Reports Positive Results From Fortetropin(R) Clinical Study

Fortetropin Significantly Reduces Serum Myostatin Levels at a Dose Approximately 40% Lower Than the Current Recommended Dose; MYOS to Present Results From Clinical Study at International Conference on Frailty & Sarcopenia Research in April

CEDAR KNOLLS, NJ — (Marketwired) — 04/22/16 — MYOS RENS Technology Inc. (“MYOS” or the “Company”) (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today the positive results of a recent clinical study which demonstrated that the daily use of 4 grams of Fortetropin, which is approximately 40% lower than the currently recommended 6.6 grams dose, results in statistically significant decreases in serum myostatin levels. A plethora of evidence has linked decreases in serum myostatin levels with gains in lean muscle mass.

“We expect the positive results of this important clinical study to contribute to the success of our aggressive commercialization strategy for Fortetropin®,” said Robert J. Hariri, M.D., Ph.D., Chairman of MYOS. Dr. Hariri continued, “at a dose as low as 4 grams per day in the broad population, along with exercise, Fortetropin may be beneficial for improving lean muscle mass, which has significant therapeutic benefits for overall health including bone density, control of serum glucose, triglyceride levels and reducing inflammation.” The Company’s abstract, entitled “A Dose-Ranging Study of the Natural Myostatin Reducing Agent, Fortetropin®, in Young Adult Males and Females” will be presented at the International Conference on Frailty & Sarcopenia Research to be held April 28-29, 2016 in Philadelphia. The clinical study, which was led by Jacob Wilson, Ph.D., CSCS*D, Assistant Professor and Director of the Skeletal Muscle and Sports Nutrition Laboratory at The University of Tampa, examined the effects of Fortetropin supplementation on serum myostatin levels at various dosing levels in young adult males and females. The purpose of this study was to enable MYOS to better define the dose response curve for Fortetropin, the minimal effective dose of Fortetropin and the effects of Fortetropin on serum myostatin. Co-authors of the clinical study from MYOS included Maghsoud Dariani, M.S., Head of Science & Technology, and Neerav D. Padliya, Ph.D., Vice President, Research Alliances.

MYOS RENS Technology Inc. | 45 Horsehill Road | Suite 106 | Cedar Knolls, NJ 07927

For more info on myostatin inhibitor and a nice PDF click here

blogleadmagnet (1)